<p>HANSOH PHARMA (03692.HK) announced that the group's independently developed innovative drug, Dacomitinib Mesylate Tablets, in combination with Amivantamab (Amivant), has had its marketing authorization application accepted by the National Medical Products Administration of China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation positive who have failed treatment with EGFR tyrosine kinase inhibitors and have mesenchymal-epithelial transition factor amplification</p>

159837

510660

03692

<p>HANSOH PHARMA announced that the group's independently developed innovative drug, methanesulfonate Dacomitinib tablets in combination with methanesulfonate Amivantamab tablets (Amivantamab?) has had its marketing authorization application accepted by the National Medical Products Administration of China, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation positive who have failed treatment with EGFR tyrosine kinase inhibitors and have mesenchymal-epithelial transition factor amplification</p>

AASTOCKS

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

HANSOH PHARMA

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

HANSOH PHARMA's application for marketing authorization of Dacomitinib Mesylate Tablets has been accepted